Reduced Bone Mass and Increased Osteocyte Tartrate‐Resistant Acid Phosphatase (TRAP) Activity, But Not Low Mineralized Matrix Around Osteocyte Lacunae, Are Restored After Recovery From Exogenous Hyperthyroidism in Male Mice
暂无分享,去创建一个
B. Busse | M. Rauner | E. Tsourdi | H. Hemmatian | S. Blouin | K. Jähn-Rickert | F. Lademann | P. Messmer | L. Hofbauer | E. Wölfel
[1] C. Heveran,et al. Lacunar-canalicular bone remodeling: impacts on bone quality and tools for assessment. , 2020, Bone.
[2] C. David,et al. Multimodal X-ray imaging of nanocontainer-treated macrophages and calcium distribution in the perilacunar bone matrix , 2020, Scientific Reports.
[3] L. Hofbauer,et al. Lack of the thyroid hormone transporter Mct8 in osteoblast and osteoclast progenitors both increases trabecular bone in male mice. , 2020, Thyroid : official journal of the American Thyroid Association.
[4] L. Bonewald,et al. Physiological and pathological osteocytic osteolysis , 2018, Journal of musculoskeletal & neuronal interactions.
[5] L. Hofbauer,et al. Sclerostin Blockade and Zoledronic Acid Improve Bone Mass and Strength in Male Mice With Exogenous Hyperthyroidism , 2017, Endocrinology.
[6] J. Bassett,et al. Thyroid diseases and bone health , 2017, Journal of Endocrinological Investigation.
[7] J. Klein-Nulend,et al. Accuracy and reproducibility of mouse cortical bone microporosity as quantified by desktop microcomputed tomography , 2017, PloS one.
[8] L. Bonewald,et al. Osteocytes Acidify Their Microenvironment in Response to PTHrP In Vitro and in Lactating Mice In Vivo , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[9] R. Ritchie,et al. Parallel mechanisms suppress cochlear bone remodeling to protect hearing. , 2016, Bone.
[10] J. Bassett,et al. Role of Thyroid Hormones in Skeletal Development and Bone Maintenance. , 2016, Endocrine reviews.
[11] L. Hofbauer,et al. Hyperthyroidism and Hypothyroidism in Male Mice and Their Effects on Bone Mass, Bone Turnover, and the Wnt Inhibitors Sclerostin and Dickkopf-1. , 2015, Endocrinology.
[12] L. Plotkin,et al. Inhibition of Osteocyte Apoptosis Prevents the Increase in Osteocytic Receptor Activator of Nuclear Factor κB Ligand (RANKL) but Does Not Stop Bone Resorption or the Loss of Bone Induced by Unloading* , 2015, The Journal of Biological Chemistry.
[13] N. Sims,et al. Quantifying the osteocyte network in the human skeleton. , 2015, Bone.
[14] Michael Hahn,et al. Osteocytic canalicular networks: morphological implications for altered mechanosensitivity. , 2013, ACS nano.
[15] Philip Kollmannsberger,et al. Architecture of the osteocyte network correlates with bone material quality , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[16] Simon Y Tang,et al. Matrix metalloproteinase–13 is required for osteocytic perilacunar remodeling and maintains bone fracture resistance , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[17] Hai Qing,et al. Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[18] L. Malaval,et al. Thyroid hormone receptor β mediates thyroid hormone effects on bone remodeling and bone mass , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[19] L. Hofbauer,et al. Approach to the patient with secondary osteoporosis. , 2010, European journal of endocrinology.
[20] Georg N Duda,et al. Increased calcium content and inhomogeneity of mineralization render bone toughness in osteoporosis: mineralization, morphology and biomechanics of human single trabeculae. , 2009, Bone.
[21] J. Wexler,et al. Thyroid and bone. , 2007, Endocrinology and metabolism clinics of North America.
[22] M. Kleerekoper,et al. Secondary osteoporosis: a review of the recent evidence. , 2006, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[23] K. Nakao,et al. A novel interaction between thyroid hormones and 1,25(OH)(2)D(3) in osteoclast formation. , 2002, Biochemical and biophysical research communications.
[24] G. Brent,et al. Thyroid hormone stimulation of osteocalcin gene expression in ROS 17/2.8 cells is mediated by transcriptional and post-transcriptional mechanisms. , 2001, The Journal of endocrinology.
[25] E. Koren,et al. Triiodothyronine Stimulates the Release of Membrane-Bound Alkaline Phosphatase in Osteoblastic Cells , 2000, Calcified Tissue International.
[26] H. Suominen,et al. Tartrate‐Resistant Acid Phosphatase 5b: A Novel Serum Marker of Bone Resorption , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[27] K. Klaushofer,et al. Triiodothyronine, a Regulator of Osteoblastic Differentiation: Depression of Histone H4, Attenuation of c-fos/c-jun, and Induction of Osteocalcin Expression , 1997, Calcified Tissue International.
[28] L. Mosekilde,et al. Bone mass, bone turnover and body composition in former hypothyroid patients receiving replacement therapy. , 1996, European journal of endocrinology.
[29] S. Cummings,et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. , 1995, The New England journal of medicine.
[30] P. Derkx,et al. A thionin stain for visualizing bone cells, mineralizing fronts and cement lines in undecalcified bone sections. , 1995, Biotechnic & histochemistry : official publication of the Biological Stain Commission.
[31] P. Delmas,et al. Markers of bone turnover in hyperthyroidism and the effects of treatment. , 1994, The Journal of clinical endocrinology and metabolism.
[32] E. Bonucci,et al. Tartrate-resistant acid phosphatase activity in rat osteoblasts and osteocytes , 1988, Calcified Tissue International.
[33] J. Harrison,et al. Effect of thyrotoxicosis and its treatment on bone mineral and muscle mass. , 1980, The Journal of clinical endocrinology and metabolism.
[34] M. Elmantaser,et al. Secondary osteoporosis. , 2009, Endocrine development.
[35] A. Parfitt,et al. The cellular basis of bone turnover and bone loss: a rebuttal of the osteocytic resorption--bone flow theory. , 1977, Clinical orthopaedics and related research.